Kyowa Kirin Drug Patent Portfolio
Kyowa Kirin owns 1 orange book drug protected by 4 US patents Given below is the list of Kyowa Kirin's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7727993 | Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy | 28 Jan, 2028 | Active |
| US8318201 | Method of stabilizing diarylvinylene compound | 05 Sep, 2027 | Active |
| US7541363 | Microcrystal | 13 Nov, 2024 | Active |
| US7727994 | Methods of treating patients suffering from movement disorders | 18 Jan, 2023 | Expired |
Latest Legal Activities on Kyowa Kirin's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Kyowa Kirin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 15 May, 2024 | US8318201 |
|
Patent Term Extension Certificate
Critical
| 17 Oct, 2023 | US7727993 |
| Notice of Final Determination -Eligible | 18 Jul, 2023 | US7727993 |
|
FDA Final Eligibility Letter
Critical
| 13 Jul, 2023 | US7727994 |
|
FDA Final Eligibility Letter
Critical
| 13 Jul, 2023 | US7727993 |
|
Interim Patent Term Extension Granted
Critical
| 22 Feb, 2023 | US7727993 |
|
Withdrawal of Application for PTE
Critical
| 22 Feb, 2023 | US7727994 |
| transaction for FDA Determination of Regulatory Review Period | 07 Nov, 2022 | US7727993 |
| transaction for FDA Determination of Regulatory Review Period | 07 Nov, 2022 | US7727994 |
|
Interim Patent Term Extension Granted
Critical
| 21 Sep, 2022 | US7727994 |
|
Interim Patent Term Extension Granted
Critical
| 21 Sep, 2022 | US7727993 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Nov, 2021 | US7727993 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Nov, 2021 | US7727994 |
| Second letter to regulating agency to determine regulatory review period | 19 Feb, 2021 | US7727993 |
| Second letter to regulating agency to determine regulatory review period | 19 Feb, 2021 | US7727994 |
Kyowa Kirin's Family Patents
Kyowa Kirin drugs have patent protection in a total of 18 countries. It's US patent count contributes only to 17.2% of its total global patent coverage. 6 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Kyowa Kirin Drug List
Given below is the complete list of Kyowa Kirin's drugs and the patents protecting them.
1. Nourianz
Nourianz is protected by 4 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7727993 | Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy |
28 Jan, 2028
(3 years from now)
| Active |
| US8318201 | Method of stabilizing diarylvinylene compound |
05 Sep, 2027
(2 years from now)
| Active |
| US7541363 | Microcrystal |
13 Nov, 2024
(29 days from now)
| Active |
| US7727994 | Methods of treating patients suffering from movement disorders |
18 Jan, 2023
(1 year, 8 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nourianz's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List